Research on DNA methylation characteristics and translational medicine have achieved multiple breakthroughs in recent years and so enhanced the power of cancer diagnostics and prognostics. Local and worldwide clinical investigations have proven that DNA methylation can be a potential biomarker for cancer detection and screening. MPap® test is the Methylation-Specific qPCR technology to qualitatively detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping. The test results can provide a reference to help doctors determine if the woman aged 40 years who is suffering from abnormal bleeding is susceptible to endometrial cancer or not, and justify further invasive endometrial sampling or other medical plans as a necessary step.
Consultation with physicians
Explanation of screening protocol
Examinee signature for Informed Consent Form
Confirmation of patient’s information and container’s label
Sampling of cervical cells
Shipping requirements of specimens
Experiment & Analysis
SBisulfite conversion reaction
DNA methylation analysis
Completion of test report
Report interpretation and health consultation
Professional evaluation and suggestions
The MPap test based on the-state-of-art DNA methylation technology in combination with non-invasive sampling process is much more comfortable and acceptable to patients than traditional invasive methods such as hysteroscopy, dilation and curettage (D&C), and endometrial biopsy.
The sensitivity and specificity of MPapⓇ test is so high that provides a more reliable risk assessment for endometrial cancer and that as a critical reference helps physicians to order confirmatory diagnostic procedure.
The MPap test is non-invasive, therefore, reduces procedural injury or discomforts in examinees.
IP rights of the technical paradigm and risk algorithm has been applied in 20+ countries, and published in internationally renowned journals, Clinical Cancer Research & Clinical Epigenetics.
Quality control has been implemented and standardized in the testing method and the corresponding clinical risk analysis to ensure the results of accuracy and credibility.